登录

Vivest Medical Secures ¥100 Million in Series A Funding from Northern Light

作者: Mailman 2021-04-26 09:08
维伟思医疗
http://www.vivest.cn
企业数据由 动脉橙 提供支持
医疗器械研发商 | PreB轮 | 运营中
中国-江苏
2022-11-21
融资金额:数亿人民币
国投创合
查看

(VCBeat) Apr. 19, 2021 -- Suzhou Vivest Medical Technology Co., Ltd. ("Vivest Medical")  announced closing a Series A funding round of nearly 100 million yuan, led by Northern Light Venture Capital, with participation from Broad Vision Funds and Bluesail Medical. Proceeds from this round will be used for new product R&D, registration, mass production and marketing.


Founded in 2019 by Mr. Zheng Jie and its founding team, Vivest Medical is an innovative medical technology company focusing on the prevention and treatment of ventricular arrhythmias and cardiac rhythm data services. For malignant arrhythmias, Vivest Medical is committed to providing the world's leading comprehensive solution from prevention, monitoring, treatment, to rehabilitation, and creating a platform for the non-invasive prevention and treatment of ventricular arrhythmias and sudden cardiac death.


Up to now, Vivest Medical has developed wearable cardioverter defibrillator (WCD) and automatic external defibrillator based on its technology and innovation capability. According to reports, Vivest Medical has the completely independent intellectual property rights of two products. Its WCD is the first of its kind in China.


On January 7, 2021, the WCD was approved by the Center for Medical Device Evaluation of the National Medical Products Administration (NMPA) for its innovation and urgent clinical needs and entered the special evaluation procedure for innovative medical devices.


>>>>

About Northern Light Venture Capital (Northern Light)


Founded in 2005, Northern Light is a venture capital firm targeting early-stage opportunities of innovation and disruptive technology. The company manages 5 USD funds and 5 RMB funds with a total amount of US$4.5 billion. Northern Light focuses on 3 main sectors including TMT, advanced technology, and healthcare.


>>>>

About Broad Vision Funds


Broad Vision Funds is a professional private equity investor, focusing on the investment of high-quality companies in the growth stage of China. The core team is composed of former executives from top investment companies such as Hony Capital and KKR, with nearly 15 years of experience in domestic and overseas equity investment on average. Broad Vision Fund invests in advanced manufacturing and healthcare industries.

注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。

Mailman

医疗行业观察者

分享
动脉橙
以上数据来自动脉橙产业智库

我们以独创的在线数据库方式,为健康产业人士提供全方位和实时的市场资讯、行业数据和分析师见解。现已覆盖数字健康、医疗器械、生物医药等近500+细分赛道,涉及公司名单、招投标、投融资信息、头部企业动态等各类数据并持续更新。

点击 【申请试用】了解动脉橙产业智库更多内容。
精彩内容推荐

【首发】「博仕康」完成数千万元A轮融资,加速“光磁一体手术导航系统”市场推广

【首发】亿索智能完成数千万元天使轮融资,专注构建吸入给药全品类、全产业链优势

Aidite Secures ¥100 Million in New Funding Round

Ewell Technology Acquires 18% equity of Yijie Medical in A Deal Worth ¥54M

Mailman

共发表文章3245篇

最近内容
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

上一篇

Demeter Closes ¥10M Series A Financing from Fortune Venture Capital

2021-04-26
下一篇

VivaVision Raises ¥300 Million in Series D Funding Round

2021-04-26